Latest
finance.yahoo.com Market update
Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences
argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, to Argenx's immunology pipeline. Both companies' boards have approved the deal, which the companies …
Main company
🇧🇪 Belgium
Read at finance.yahoo.com